logo

Select Sidearea

Populate the sidearea with useful widgets. It’s simple to add images, categories, latest post, social media icon links, tag clouds, and more.
hello@youremail.com
+1234567890
 

ANANDA Scientific & Chronic Pain

The Science Behind It All...

ANANDA Scientific and Chronic Pain

Chronic pain is an enormous worldwide problem. About 20% of adults suffer from it and 10% are newly diagnosed each year. Chronic pain currently impacts 116,000 Americans, more than 100 million people in China, 55 million in Europe and 61 million in India. The market for pain-relieving medicine is understandably huge, and with its growth is being significantly driven by aging world demographics.

The market for pain-relieving medicines exceeded $20 billion in the United States and $50 billion worldwide in 2011 – and has been growing at 4% per year for a long time.

Opioids accounted for about $9 billion of the $20 billion United States market in 2011, and it continues to dominate as medicine for pain management. The large market share held by opioids is unfortunately been accompanied by an epidemic of overdose deaths, with prescription opioid mortalities in the US now exceeding the number of people dying from heroin and cocaine combined. There were about 16,000 unintentional opioid deaths in 2013. Opioids are also responsible for almost 500,000 emergency room hospital visits each year. In other words, the consequences of opioid use are a public health nightmare. Furthermore, there is a collective cultural fear of opioids in China rooted in the Opium Wars during the 1800s that led to rampant addiction nationwide. Now, pain patients are not offered or refuse opioids. They instead suffer because effective, non- addictive alternatives are not available.

There is a great unmet need for  effective therapeutics with minimal abuse potential. In that regard, non-psychoactive and non-addictive cannabidiol (CBD) seems effective and safe. Consequently, ANANDA Scientific has arranged for clinical studies of CBD and pain management at two major Israeli hospitals. CBD as an analgesic will also be pursued in China, where it is a cultural and regulatory fit. Indeed, the Traditional Chinese Medicine Pharmacopeia shows it was used for pain relief over 1,700 years ago.

The market share held by opioids is unfortunately been accompanied by an epidemic of overdose deaths, with prescription opioid mortalities in the US now exceeding the number of people dying from heroin and cocaine combined. There were about 16,000 unintentional opioid deaths in 2013. Opioids are also responsible for almost 500,000 emergency room hospital visits each year. In other words, the consequences of opioid use are a public health nightmare. Furthermore, there is a collective cultural fear of opioids in China rooted in the Opium Wars during the 1800s that led to rampant addiction nationwide. Now, pain patients are not offered or refuse opioids. They instead suffer because effective, non–addictive alternatives are not available.

ANANDA Scientific’s Breakthrough Research & Development and Strategic Global Perspective Lay the Groundwork for Sustained Success and for Maintaining a High Barrier to Entry for Competitors.
  • Large-scale industrial manufacturing capacity – distinctive ability to legally produce substantial amounts of non-psychoative CBD (but also other cannabinoids).
  • Consistent, enhanced closing of CBD achieved – an unmet need uniquely resolved by ANANDA Scientific and an industry first.
  • Done with patent-protected, proprietary ANANDA Particulate Technology™ GRAS (deemed safe by the USFDA) technology.
  • Necessary intellectual property otherwise in place for processes related to CBD production as well as its medicinal use (to treat adverse health conditions affecting millions, thus large potential market(s); additional proprietary, patentable innovations forthcoming.
  • Standardization to warrant product purity, consistency and quality.
  • Core efforts situated where best suited, in the US, Israel, China or Canada.
  • Partnered with leading scientists, physicians, and industry leaders around the world.
  • R&D underway at major scientific and medical institutions.
  • Science-based preclinical and human clinical studies in process.
  • Expedited regulatory approval for CBD to treat diabetes likely in China, a huge market of 114 million patients, one third of all diabeticvs.